AtriCure, Inc. (NASDAQ: ATRC) recently announced the appointment of Shlomi Nachman to its board of directors. This move comes as the company continues its mission of providing innovative surgical treatments and therapies for atrial fibrillation (AFib), left atrial appendage (LAA) management, and post-operative pain management.
Nachman brings over 25 years of experience in the medical device industry, with a notable career at Johnson & Johnson's medical devices business, where he served as the company group chairman. His extensive background in new market development and growth positions him as a valuable addition to AtriCure's board.
In response to his appointment, Nachman expressed his excitement about joining AtriCure during a time of accelerating growth and profitability. He emphasized the untapped opportunities in the AFib treatment market and highlighted AtriCure's potential to address a segment of the market that includes significantly underserved patients. Nachman's confidence in the company's business, prospects, and end user markets underscores his belief in AtriCure's underpenetrated potential.
Michael Carrel, President and CEO of AtriCure, welcomed Nachman to the board, noting his reputation as one of the most well-respected leaders in the medical device space. Carrel highlighted Nachman's experience in the AFib market as particularly invaluable to AtriCure as it continues its mission of healing the lives of those affected by this global epidemic.
AtriCure, Inc. is known for its innovative technologies for the treatment of AFib and related conditions, serving electrophysiologists and cardiothoracic surgeons worldwide. The company's Isolator® Synergy™ Ablation System, AtriClip® Left Atrial Appendage Exclusion System, and Hybrid AF™ Therapy are among the groundbreaking solutions aimed at addressing the needs of patients with AFib.
The company's full 8-K submission is available here.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Revenue (k) | $201,630 | $230,807 | $206,531 | $274,329 | $330,379 | $380,730 |
| Revenue Growth | n/a | 14.47% | -10.52% | 32.83% | 20.43% | 15.24% |
| Operating Margins | -8% | -14% | -21% | 20% | -13% | -6% |
| Net Margins | -10% | -15% | -23% | 18% | -14% | -7% |
| Net Income (k) | -$21,137 | -$35,194 | -$48,155 | $50,199 | -$46,466 | -$24,819 |
| Net Interest Expense (k) | $4,607 | $4,111 | $4,885 | $4,918 | $4,986 | $6,688 |
| Depreciation & Amort. (k) | $7,244 | $7,423 | $7,866 | $7,534 | $8,057 | $9,159 |
| Earnings Per Share | $34087 | $37589 | $42125 | $1.09 | -$1.02 | -$0.55 |
| Diluted Shares (k) | 34,087 | 37,589 | 42,125 | 46,039 | 45,740 | 46,411 |
| Free Cash Flow (k) | -$10,382 | -$27,993 | -$25,128 | -$23,533 | -$39,022 | -$12,883 |
| Capital Expenditures | $6,211 | $12,182 | $5,259 | $9,753 | $16,881 | $13,383 |
| Current Ratio | 4.34 | 2.87 | 6.24 | 3.47 | 3.69 | 3.06 |
| Total Debt (k) | $53,079 | $62,218 | $68,417 | $61,756 | $65,472 | $60,000 |
